A citation-based method for searching scientific literature

Xavier Montalban, Stephen L Hauser, Ludwig Kappos, Douglas L Arnold, Amit Bar-Or, Giancarlo Comi, Jérôme de Seze, Gavin Giovannoni, Hans-Peter Hartung, Bernhard Hemmer, Fred Lublin, Kottil W Rammohan, Krzysztof Selmaj, Anthony Traboulsee, Annette Sauter, Donna Masterman, Paulo Fontoura, Shibeshih Belachew, Hideki Garren, Nicole Mairon, Peter Chin, Jerry S Wolinsky. N Engl J Med 2017
Times Cited: 892







List of co-cited articles
879 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis.
Stephen L Hauser, Amit Bar-Or, Giancarlo Comi, Gavin Giovannoni, Hans-Peter Hartung, Bernhard Hemmer, Fred Lublin, Xavier Montalban, Kottil W Rammohan, Krzysztof Selmaj,[...]. N Engl J Med 2017
861
52

Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial.
Kathleen Hawker, Paul O'Connor, Mark S Freedman, Peter A Calabresi, Jack Antel, Jack Simon, Stephen Hauser, Emmanuelle Waubant, Timothy Vollmer, Hillel Panitch,[...]. Ann Neurol 2009
604
27

Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study.
Ludwig Kappos, Amit Bar-Or, Bruce A C Cree, Robert J Fox, Gavin Giovannoni, Ralf Gold, Patrick Vermersch, Douglas L Arnold, Sophie Arnould, Tatiana Scherz,[...]. Lancet 2018
437
26

Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria.
Alan J Thompson, Brenda L Banwell, Frederik Barkhof, William M Carroll, Timothy Coetzee, Giancarlo Comi, Jorge Correale, Franz Fazekas, Massimo Filippi, Mark S Freedman,[...]. Lancet Neurol 2018
25

Defining the clinical course of multiple sclerosis: the 2013 revisions.
Fred D Lublin, Stephen C Reingold, Jeffrey A Cohen, Gary R Cutter, Per Soelberg Sørensen, Alan J Thompson, Jerry S Wolinsky, Laura J Balcer, Brenda Banwell, Frederik Barkhof,[...]. Neurology 2014
25

B-cell depletion with rituximab in relapsing-remitting multiple sclerosis.
Stephen L Hauser, Emmanuelle Waubant, Douglas L Arnold, Timothy Vollmer, Jack Antel, Robert J Fox, Amit Bar-Or, Michael Panzara, Neena Sarkar, Sunil Agarwal,[...]. N Engl J Med 2008
23

Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology.
Roberta Magliozzi, Owain Howell, Abhilash Vora, Barbara Serafini, Richard Nicholas, Maria Puopolo, Richard Reynolds, Francesca Aloisi. Brain 2007
916
18

Ofatumumab versus Teriflunomide in Multiple Sclerosis.
Stephen L Hauser, Amit Bar-Or, Jeffrey A Cohen, Giancarlo Comi, Jorge Correale, Patricia K Coyle, Anne H Cross, Jerome de Seze, David Leppert, Xavier Montalban,[...]. N Engl J Med 2020
169
18

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis.
Chris H Polman, Paul W O'Connor, Eva Havrdova, Michael Hutchinson, Ludwig Kappos, David H Miller, J Theodore Phillips, Fred D Lublin, Gavin Giovannoni, Andrzej Wajgt,[...]. N Engl J Med 2006
17

Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial.
Jerry S Wolinsky, Douglas L Arnold, Bruno Brochet, Hans-Peter Hartung, Xavier Montalban, Robert T Naismith, Marianna Manfrini, James Overell, Harold Koendgen, Annette Sauter,[...]. Lancet Neurol 2020
50
32

Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial.
Fred Lublin, David H Miller, Mark S Freedman, Bruce A C Cree, Jerry S Wolinsky, Howard Weiner, Catherine Lubetzki, Hans-Peter Hartung, Xavier Montalban, Bernard M J Uitdehaag,[...]. Lancet 2016
271
16

Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial.
Ludwig Kappos, David Li, Peter A Calabresi, Paul O'Connor, Amit Bar-Or, Frederik Barkhof, Ming Yin, David Leppert, Robert Glanzman, Jeroen Tinbergen,[...]. Lancet 2011
482
15

Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension.
Stephen L Hauser, Ludwig Kappos, Douglas L Arnold, Amit Bar-Or, Bruno Brochet, Robert T Naismith, Anthony Traboulsee, Jerry S Wolinsky, Shibeshih Belachew, Harold Koendgen,[...]. Neurology 2020
50
28

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial.
Alasdair J Coles, Cary L Twyman, Douglas L Arnold, Jeffrey A Cohen, Christian Confavreux, Edward J Fox, Hans-Peter Hartung, Eva Havrdova, Krzysztof W Selmaj, Howard L Weiner,[...]. Lancet 2012
786
13

Pathological mechanisms in progressive multiple sclerosis.
Don H Mahad, Bruce D Trapp, Hans Lassmann. Lancet Neurol 2015
652
13

Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis: The VELOCE study.
Amit Bar-Or, Jonathan C Calkwood, Cathy Chognot, Joanna Evershed, Edward J Fox, Ann Herman, Marianna Manfrini, John McNamara, Derrick S Robertson, Daniela Stokmaier,[...]. Neurology 2020
191
12

Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis.
Maria P Sormani, Nicola De Rossi, Irene Schiavetti, Luca Carmisciano, Cinzia Cordioli, Lucia Moiola, Marta Radaelli, Paolo Immovilli, Marco Capobianco, Maria Trojano,[...]. Ann Neurol 2021
242
12

Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis.
Owain W Howell, Cheryl A Reeves, Richard Nicholas, Daniele Carassiti, Bishan Radotra, Steve M Gentleman, Barbara Serafini, Francesca Aloisi, Federico Roncaroli, Roberta Magliozzi,[...]. Brain 2011
510
12

The relation between inflammation and neurodegeneration in multiple sclerosis brains.
Josa M Frischer, Stephan Bramow, Assunta Dal-Bianco, Claudia F Lucchinetti, Helmut Rauschka, Manfred Schmidbauer, Henning Laursen, Per Soelberg Sorensen, Hans Lassmann. Brain 2009
921
12

Multiple sclerosis.
Alan J Thompson, Sergio E Baranzini, Jeroen Geurts, Bernhard Hemmer, Olga Ciccarelli. Lancet 2018
797
12

Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension.
Raju Kapoor, Pei-Ran Ho, Nolan Campbell, Ih Chang, Aaron Deykin, Fiona Forrestal, Nisha Lucas, Bei Yu, Douglas L Arnold, Mark S Freedman,[...]. Lancet Neurol 2018
167
12

Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Bruce A C Cree, Gary Cutter, Jerry S Wolinsky, Mark S Freedman, Giancarlo Comi, Gavin Giovannoni, Hans-Peter Hartung, Douglas Arnold, Jens Kuhle, Valerie Block,[...]. Lancet Neurol 2020
42
28

Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies.
Gustavo Luna, Peter Alping, Joachim Burman, Katharina Fink, Anna Fogdell-Hahn, Martin Gunnarsson, Jan Hillert, Annette Langer-Gould, Jan Lycke, Petra Nilsson,[...]. JAMA Neurol 2020
240
11

Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis.
Xavier Montalban, Douglas L Arnold, Martin S Weber, Ivan Staikov, Karolina Piasecka-Stryczynska, Jonathan Willmer, Emily C Martin, Fernando Dangond, Sana Syed, Jerry S Wolinsky. N Engl J Med 2019
139
11

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.
Richard A Rudick, William H Stuart, Peter A Calabresi, Christian Confavreux, Steven L Galetta, Ernst-Wilhelm Radue, Fred D Lublin, Bianca Weinstock-Guttman, Daniel R Wynn, Frances Lynn,[...]. N Engl J Med 2006
960
11

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial.
Jeffrey A Cohen, Alasdair J Coles, Douglas L Arnold, Christian Confavreux, Edward J Fox, Hans-Peter Hartung, Eva Havrdova, Krzysztof W Selmaj, Howard L Weiner, Elizabeth Fisher,[...]. Lancet 2012
795
11


A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.
Gavin Giovannoni, Giancarlo Comi, Stuart Cook, Kottil Rammohan, Peter Rieckmann, Per Soelberg Sørensen, Patrick Vermersch, Peter Chang, Anthony Hamlett, Bruno Musch,[...]. N Engl J Med 2010
542
11

Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis.
Barbara Serafini, Barbara Rosicarelli, Roberta Magliozzi, Egidio Stigliano, Francesca Aloisi. Brain Pathol 2004
810
10

Proinflammatory GM-CSF-producing B cells in multiple sclerosis and B cell depletion therapy.
Rui Li, Ayman Rezk, Yusei Miyazaki, Ellen Hilgenberg, Hanane Touil, Ping Shen, Craig S Moore, Laure Michel, Faisal Althekair, Sathy Rajasekharan,[...]. Sci Transl Med 2015
249
10

Randomized trial of oral teriflunomide for relapsing multiple sclerosis.
Paul O'Connor, Jerry S Wolinsky, Christian Confavreux, Giancarlo Comi, Ludwig Kappos, Tomas P Olsson, Hadj Benzerdjeb, Philippe Truffinet, Lin Wang, Aaron Miller,[...]. N Engl J Med 2011
615
10

Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial.
Giancarlo Comi, Ludwig Kappos, Krzysztof W Selmaj, Amit Bar-Or, Douglas L Arnold, Lawrence Steinman, Hans-Peter Hartung, Xavier Montalban, Eva Kubala Havrdová, Bruce A C Cree,[...]. Lancet Neurol 2019
110
10


Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties.
Christian Klein, Alfred Lammens, Wolfgang Schäfer, Guy Georges, Manfred Schwaiger, Ekkehard Mössner, Karl-Peter Hopfner, Pablo Umaña, Gerhard Niederfellner. MAbs 2013
197
9

Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS?
Amit Bar-Or, Lama Fawaz, Boli Fan, Peter J Darlington, Aja Rieger, Christine Ghorayeb, Peter A Calabresi, Emmanuelle Waubant, Stephen L Hauser, Jiameng Zhang,[...]. Ann Neurol 2010
331
9

Memory B Cells Activate Brain-Homing, Autoreactive CD4+ T Cells in Multiple Sclerosis.
Ivan Jelcic, Faiez Al Nimer, Jian Wang, Verena Lentsch, Raquel Planas, Ilijas Jelcic, Aleksandar Madjovski, Sabrina Ruhrmann, Wolfgang Faigle, Katrin Frauenknecht,[...]. Cell 2018
227
9

Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR study.
Amit Bar-Or, Richard A Grove, Daren J Austin, Jerry M Tolson, Susan A VanMeter, Eric W Lewis, Frederick J Derosier, Monica C Lopez, Sarah T Kavanagh, Aaron E Miller,[...]. Neurology 2018
97
9

The ocrelizumab phase II extension trial suggests the potential to improve the risk: Benefit balance in multiple sclerosis.
David Baker, Gareth Pryce, Louisa K James, Monica Marta, Klaus Schmierer. Mult Scler Relat Disord 2020
50
18

Multiple Sclerosis: Mechanisms and Immunotherapy.
Clare Baecher-Allan, Belinda J Kaskow, Howard L Weiner. Neuron 2018
388
9

Immunopathology of multiple sclerosis.
Calliope A Dendrou, Lars Fugger, Manuel A Friese. Nat Rev Immunol 2015
9

Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial.
Hans-Peter Hartung, Richard Gonsette, Nikolaus König, Hubert Kwiecinski, Andreas Guseo, Sean P Morrissey, Hilmar Krapf, Thomas Zwingers. Lancet 2002
643
9

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.
Jeffrey A Cohen, Frederik Barkhof, Giancarlo Comi, Hans-Peter Hartung, Bhupendra O Khatri, Xavier Montalban, Jean Pelletier, Ruggero Capra, Paolo Gallo, Guillermo Izquierdo,[...]. N Engl J Med 2010
9

Multiple Sclerosis.
Daniel S Reich, Claudia F Lucchinetti, Peter A Calabresi. N Engl J Med 2018
987
9

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.
Ludwig Kappos, Ernst-Wilhelm Radue, Paul O'Connor, Chris Polman, Reinhard Hohlfeld, Peter Calabresi, Krzysztof Selmaj, Catherine Agoropoulou, Malgorzata Leyk, Lixin Zhang-Auberson,[...]. N Engl J Med 2010
9

Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis.
Robert J Fox, Christopher S Coffey, Robin Conwit, Merit E Cudkowicz, Trevis Gleason, Andrew Goodman, Eric C Klawiter, Kazuko Matsuda, Michelle McGovern, Robert T Naismith,[...]. N Engl J Med 2018
141
9

Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy.
Sokratis A Apostolidis, Mihir Kakara, Mark M Painter, Rishi R Goel, Divij Mathew, Kerry Lenzi, Ayman Rezk, Kristina R Patterson, Diego A Espinoza, Jessy C Kadri,[...]. Nat Med 2021
216
9

Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials.
Ludwig Kappos, Jerry S Wolinsky, Gavin Giovannoni, Douglas L Arnold, Qing Wang, Corrado Bernasconi, Fabian Model, Harold Koendgen, Marianna Manfrini, Shibeshih Belachew,[...]. JAMA Neurol 2020
103
9

Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial.
Jeffrey A Cohen, Giancarlo Comi, Krzysztof W Selmaj, Amit Bar-Or, Douglas L Arnold, Lawrence Steinman, Hans-Peter Hartung, Xavier Montalban, Eva Kubala Havrdová, Bruce A C Cree,[...]. Lancet Neurol 2019
103
8

Reassessing B cell contributions in multiple sclerosis.
Rui Li, Kristina R Patterson, Amit Bar-Or. Nat Immunol 2018
187
8

Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial.
Amit Bar-Or, Peter A J Calabresi, Douglas Arnold, Clyde Markowitz, Stuart Shafer, Lloyd H Kasper, Emmanuelle Waubant, Suzanne Gazda, Robert J Fox, Michael Panzara,[...]. Ann Neurol 2008
379
8


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.